The anti-EGFR antibody cetuximab used in combination with radiotherapy or chemotherapy exhibited a significant clinical benefit when used against head and neck squamous cell carcinoma (28,29), leading to an ongoing intensive clinical trial using cetuximab for the treatment of ESCC. The gene discussed is EGFR; the disease is esophageal squamous cell carcinoma.